In XOI (+) group, 81.3% of subjects were administered angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), of whom 32.1% had cardiovascular disease, while 44.9% of XOI (+) without ACEi or ARB had cardiovascular disease. Here, ACE is linked to cardiovascular disorder.